Physician profile
Leonard R Baker
NPI 1255453627
$16,805.61
in general payments reported to CMS, 2019-2025
12 companies · $436 in 2025
The $436 reported for 2025 was more than what 84% of Developmental - Behavioral Pediatrics providers received nationally (typical 2025 total: $79.84).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $5,515 · 2021: $4,285 · 2022: $4,312 · 2023: $1,033 · 2024: $878 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,841 · Honoraria: $500 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,841.40 |
| Honoraria | $500.00 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $12,289.64 | 2019-2024 | Dyanavel Xr, Quillivant, Quillichew Er |
| Adlon Therapeutics L.P. | $2,041.14 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $888.51 | 2022-2025 | Qelbree, Qelbree |
| Corium, LLC | $491.83 | 2022-2025 | Azstarys, Azstarys |
| Ironshore Pharmaceuticals INC. | $355.21 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $249.58 | 2020-2021 | |
| Neos Therapeutics, Lp | $166.25 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Vertical Pharmaceuticals, LLC | $133.50 | 2019-2025 | Relexxii |
| Collegium Pharmaceutical, INC. | $113.95 | 2025 | Jornay Pm |
| Shire North American Group INC | $41.66 | 2019 | |
| Avion Pharmaceuticals | $23.44 | 2023 | Methylphenidate Hydrochloride |
| Arbor Pharmaceuticals, INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.